BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Cao Y, Zhang R, Zhang X, Lu H, Wu C, Huo N, Xu X. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients. PLoS One 2016;11:e0165658. [PMID: 27812165 DOI: 10.1371/journal.pone.0165658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sakurai F, Hashimoto R, Inoue C, Wakabayashi K, Tsukamoto T, Imaizumi T, Andres TGM, Sakai E, Itsuki K, Sakamoto N, Wakita T, Mizuguchi H. miR-27b-mediated suppression of aquaporin-11 expression in hepatocytes reduces HCV genomic RNA levels but not viral titers. Virol J 2019;16:58. [PMID: 31046802 DOI: 10.1186/s12985-019-1160-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Uchida Y, Nakamura S, Kouyama JI, Naiki K, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Hedskog C, Brainard D, Mo H, Mochida S. Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis. Sci Rep 2018;8:8818. [PMID: 29892096 DOI: 10.1038/s41598-018-27291-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
3 Nejabat N, Hosseini SY, Sarvari J, Gorzin AA, Fattahi MR, Rasoolian M. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients. Asian Pac J Cancer Prev 2019;20:2311-7. [PMID: 31450900 DOI: 10.31557/APJCP.2019.20.8.2311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Kao JH, Yu ML, Chen CY, Peng CY, Chen MY, Tang H, Chen Q, Wu JJ. Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study. J Gastroenterol Hepatol 2018;33:1507-10. [PMID: 29346834 DOI: 10.1111/jgh.14096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Xu X, Feng B, Guan Y, Zheng S, Sheng J, Yang X, Ma Y, Huang Y, Kang Y, Wen X, Li J, Tan Y, He Q, Xie Q, Wang M, An P, Gong G, Liu H, Ning Q, Hua R, Ning B, Xie W, Zhang J, Huang W, Yang Y, Lin M, Zhao Y, Yu Y, Jia J, Yang D, Chen L, Ye Y, Nan Y, Gong Z, Zhang Q, Hu P, Wang F, Li Y, Li D, Jia Z, Hou J, Chen C, Wu JJ, Wei L. Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China. J Clin Transl Hepatol 2019;7:213-20. [PMID: 31608212 DOI: 10.14218/JCTH.2019.00033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
6 Lu J, Feng Y, Chen L, Zeng Z, Liu X, Cai W, Wang H, Guo X, Zhou H, Tao W, Xie Q. Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. Front Microbiol 2019;10:535. [PMID: 30941111 DOI: 10.3389/fmicb.2019.00535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
7 Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Fajardo A, Soñora M, Cristina J, Hernández N, Moreno P. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients. Dis Markers 2018;2018:2514901. [PMID: 30186532 DOI: 10.1155/2018/2514901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]